You are here

Biocryst

BioCryst hits another hurdle, delays trial for its 1 remaining clinical candidate

Fierce Biotech

Fri, 02/24/23 - 08:58 am

complement-mediated diseases

clinical trials

45 days later, BioCryst abandons another program, citing stiff competition

Fierce Biotech

Thu, 12/15/22 - 11:07 am

BioCryst leaves ultra-rare bone disease efforts in hands of Ipsen, Regeneron with discontinuation

Fierce Biotech

Tue, 11/1/22 - 11:00 am

fibrodysplasia ossificans progressiva

BioCryst's Orladeyo Launch Overshadowed by FDA Hold on PNH Asset

BioSpace

Sun, 05/8/22 - 12:09 pm

After Falling 21% in a Month, Is There Any Hope for BioCryst Pharmaceuticals?

Motley Fool

Tue, 04/19/22 - 11:00 am

BioCryst halts enrollment in all studies for its lead pipeline candidate — shares crash

Endpoints

Fri, 04/8/22 - 10:47 am

clinical trials

BioCryst gets massive cash infusion to the tune of $350M, thanks to old and new investors

Endpoints

Mon, 11/22/21 - 10:12 pm

BioCryst scraps $200M offering after seeing share price slide

Fierce Biotech

Wed, 08/11/21 - 12:08 pm

BioCryst's persistence for patient insights leads to a bigger market for HAE drug Orladeyo

Fierce Pharma

Tue, 05/25/21 - 11:53 pm

Fortunes diverge for solo drug launchers

EP Vantage

Tue, 05/11/21 - 11:01 am

Intra-Cellular Therapies

Horizon Therapeutics

Karyopharm Therapeutics

Blueprint Medicines

Aurinia Pharmaceuticals

Global Blood Therapeutics

Biocryst looks to raise the profile of its factor D inhibitor

EP Vantage

Tue, 02/23/21 - 10:33 am

factor D inhibitors

BioCryst takes on Takeda, CSL with FDA approval for Orladeyo, the first pill to prevent HAE attacks

Fierce Pharma

Sat, 12/5/20 - 11:26 pm

BioCryst Plans to Raise $100 Million

Motley Fool

Wed, 05/27/20 - 11:51 pm

BioCryst Is Testing Galidesivir for COVID-19

Motley Fool

Sat, 04/11/20 - 10:55 pm

BioCryst starts COVID-19 trial of broad-spectrum antiviral

Fierce Biotech

Fri, 04/10/20 - 10:24 am

clinical trials

5 Biotechs to Watch With the Coronavirus Scare

Motley Fool

Sun, 01/26/20 - 01:44 pm

Wuhan Coronavirus

Gilead Sciences

Moderna Therapeutics

After BioCryst fizzle, a new oral HAE player emerges

Endpoints

Tue, 09/10/19 - 11:10 am

clinical trials

Upcoming events – key tests approach for Biogen and Kalvista

EP Vantage

Fri, 05/24/19 - 10:42 am

multiple sclerosis

BioCryst shares are blasted as a PhIII HAE 'success' underwhelms analysts

Endpoints

Tue, 05/21/19 - 09:51 am

clinical trials

BioCryst says oral drug works for HAE attacks

Fierce Biotech

Tue, 09/4/18 - 11:02 am

clinical trials

hereditary angiodema

Pages